You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤前公告 | 輝瑞以約2億美元認購基石藥業9.9%的股份
uSMART友信智投 09-30 08:30

uSMART友信智投9月30日消息,基石藥業-B在披露易發佈公告稱,於2020年9月30日(交易時段前),本公司與輝瑞訂立股份認購協議,據此,輝瑞已有條件同意按認購價每股股份約13.37港元認購股份,於最後交易日,聯交所所報的每股股份收市價爲9.30港元

也就是說,收購價較最後收市價溢價約43.8%

配發及發行認購股份的所得款項總額將爲約2億美元(相當於約15.5億港元)。

認購股份佔本公司經配發及發行認購股份擴大後的已發行股本9.90%

基石藥業同意授予輝瑞獨家許可,商業化CS1001

CS1001是基石藥業開發的、有望成爲同類最優的一款PD-L1抗體,其潛在適應症涵蓋肺癌、胃癌和食管癌等多箇中國高發癌症類型。此項合作爲基石藥業進一步開發CS1001提供了資金支持。

點擊可跳轉閱讀《基石藥業-B根據一般授權發行認購股份及與PFIZER INVESTMENT進行戰略合作》公告原文件PDF。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account